Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema, and more.

Enter Eli Lilly (NYSE ... consider that Lilly's market value is larger than Pfizer's, Moderna's, and J&J's combined! Moreover, Novo Nordisk is now the most valuable company in Europe -- ahead ...

Moreover, Novo Nordisk is now the most valuable company in Europe -- ahead of luxury ... 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made ...

Moreover, Novo Nordisk is now the most valuable company in Europe -- ahead of luxury fashion powerhouse LVMH Moët Hennessy. While it's clear that Lilly and Novo Nordisk are having a moment right ...

In the third quarter, Eli Lilly's sales grew by 20% year over year to $11.4 billion, largely thanks to Zepbound and Mounjaro. But the company's ... For that matter, CagriSema performed better ...

The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a welcome predicament: What to do with all that cash? One answer ...

Eli Lilly is a big name in diabetes care and weight loss. Tirzepatide generates billions in revenue for the healthcare company ... it could be a matter of time before the Food and Drug ...